Matrix metalloproteinase-9 is increased and correlates with severity in Guillain-Barre syndrome

Neurology

Volumn 53, Issue 8, 1999, Pages 1683-1691

  Créange, Alain ^a,b   Sharshar, T ^a,c   Planchenault, T ^a   Christov, C ^a   Poron, F ^a   Raphael J C ^a,c   Gherardi, R K ^a,b  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

Demyelinating neuropathy; Guillain Barre syndrome; Inflammation; Metalloproteinase

Indexed keywords

GELATINASE A; GELATINASE B; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LYMPHOCYTE; MONONUCLEAR CELL; MYELINATED NERVE; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; ZYMOGRAPHY;

EID: 0345533956     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.8.1683     Document Type: Article

References (53)

1. Hartung HP, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome, part I. Muscle Nerve 1995;18:137-153.
2. Yuki N, Taki T, Takahashi M, et al. Penner's serotype 4 of Campylobacter jejuni has a lipopolysaccharide that bears a GM1 ganglioside epitope as well as one that bears a GD1a epitope. Infect Immun 1994;62:2101-2103.
3. Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996;40:635-644.
4. Hartung H-P, Heiners K, Schmidt B, Stoll G, Toyka KV. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol 1991;30:48-53.
5. Créange A, Belec L, Clerc B, Raphael J-C, Gherardi RK. Differential kinetics of circulating tumor necrosis factor (TNF)-α and soluble TNF receptor (sTNF-Rs) in patients with Guillain-Barré syndrome. J Neuroimmunol 1996;68:95-99.
6. Asbury AK, Arnason BG, Adams R. The inflammatory lesion in idiopathic polyneuritis. Medicine 1969;48:173-215.
7. Lorimier P, Mezin P, Labat Moleur F, et al. Ultrastructural localization of the major components of the extracellular matrix in normal rat nerve. J Histochem Cytochem 1992;40:859-868.
8. Ries C, Petrides PE. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem 1995;376:345-355.
9. Murphy G, Docherty AJP. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 1992;7:120-125.
10. Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992;41:29-34.
11. Cuzner ML, Gveric D, Strand C, et al. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 1996;55:1194-1204.
12. Proost P, Van Damme J, Opdenakker G. Leucocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 1993;192:1175-1181.
13. Redford EJ, Smith KJ, Gregson NA, et al. A combined inhibitor of matrix metalloproteinase activity and tumor necrosis factor-α processing attenuates experimental autoimmune neuritis. Brain 1997;120:1895-1905.
14. Hughes PM, Wells GMA, Clements JM, et al. Matrix metalloproteinase expression during experimental autoimmune neuritis. Brain 1998;121:481-494.
15. Kieseier BC, Clements JM, Pischel HB, et al. Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré syndrome. Ann Neurol 1998;43:427-434.
16. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27(suppl):S21-S24.
17. Hughes RAC, Newsom-Davis JM, Perkins JD. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978;2:750-753.
18. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980; 102:196-202.
19. Doucet JP, Trifaro JM. A discontinuous and highly porous sodium dodecyl sulfate-polyacrylamide slab gel system of high resolution. Anal Biochem 1988;168:265-271.
20. Herron GS, Werb Z, Dwyer K, Banda MJ. Secretion of metalloproteinases by stimulated capillary endothelial cells. I. Production of procollagenase and prostromelysin exceeds expression of proteolytic activity. J Biol Chem 1986;261:2810-2813.
21. Opdenakker G, Masure S, Proost P, Billiau A, van Damme J. Natural human monocyte gelatinase and its inhibitor. FEBS Lett 1991;284:73-78.
22. Montgomery AMP, Sabzevari H, Reisfeld RA. Production and regulation of gelatinase B by human T cells. Biochim Biophys Acta 1993;1176:265-268.
23. Masure S, Proost P, Van Damme J, Opdenakker G. Purification and identification of 91-kDa neutrophil gelatinase: release by the activating peptide interleukin-8. Eur J Biochem 1991;198:391-398.
24. La Fleur M, Underwood JL, Rappolee DA, Werb Z. Basement membrane and repair of injury to peripheral nerve: defining a potential role for macrophages, matrix metalloproteinases, and tissue inhibitor of metalloproteinases-1. J Exp Med 1996; 184:2311-2326.
25. Backstrom JR, Lim GP, Cullen MJ, Tokes ZA. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J Neurosci 1996;16:7910-7919.
26. Gearing AJ, Beckett P, Christodoulou M, et al. Processing of tumor necrosis factor-α by metalloproteinases. Nature 1994; 370:555-557.
27. Nakagawa H, Kitagawa H, Aikawa Y. Tumor necrosis factor stimulates gelatinase and collagenase production by granulation tissue in culture. Biochem Biophys Res Commun 1987; 142:791-797.
28. Johnatty RN, Taub DD, Reeder SP, et al. Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J Immunol 1997;158: 2327-2333.
29. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76: 301-314.
30. Hartung HP, Reiners K, Michels M, et al. Serum levels of soluble E-selectin (ELAM-1) in immune-mediated neuropathies. Neurology 1994;44:1153-1158.
31. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995;154:4379-4389.
32. Heino J. Biology of tumor cell invasion: interplay of cell adhesion and matrix degradation. Int J Cancer 1996;65:717-722.
33. Larjava H, Lyons JG, Salo T, et al. Anti-integrin antibodies induce type IV collagenase expression in keratinocytes. J Cell Physiol 1993;157:190-200.
34. Leibovich SJ. Role of cytokines in the process of tumor angiogenesis. In: Aggarwal BB, Puri RK, eds. Human cytokines: their role in disease and therapy. Cambridge, MA: Blackwell Science, 1995:539-564.
35. Aoudjit F, Potworowski EF, St. Pierre Y. Bi-directional induction of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 during T lymphoma/endothelial cell contact: implication of ICAM-1. J Immunol 1998;160:2967-2973.
36. Romanic AM, Madri JA. The induction of 72-kD gelatinase in T cells upon adhesion to endothelial cells is VCAM-1 dependent. J Cell Biol 1994;125:1165-1178.
37. Schlaak JF, Claus C, Meyer, Zum Buschenfelde KH, et al. Anti-GD3 antibodies are potent activators of human gamma/delta and alpha/beta positive T cells. Scand J Immunol 1995; 41:475-480.
38. Kanda N, Tamaki K. Ganglioside GQ1b enhances Ig production by human PBMCs. J Allergy Clin Immunol 1998;102: 813-820.
39. Maidment SL, Merzak A, Koochekpour S, et al. The effect of exogenous gangliosides on matrix metalloproteinase secretion by human glioma cells in vitro. Eur J Cancer 1996;32A:868-871.
40. Redford EJ, Hall SM, Smith KJ. Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor. Brain 1995;118:869-878.
41. Selmaj K, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocytes damage in vitro. Ann Neurol 1988;23: 339-346.
42. Chandler S, Coates R, Gearing A, et al. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 1995; 201:223-226.
43. Madri JA, Graesser D, Haas T. The roles of adhesion molecules and proteinases in lymphocyte transendothelial migration. Biochem Cell Biol 1996;74:749-757.
44. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997;378:151-160.
45. Dean DD, Martel-Pelletier J, Pelletier J-P, Howell DS, Woessner JF. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 1989;84:678-685.
46. Baker T, Tickle S, Wasan H, et al. Serum metalloproteinases and their inhibitors: markers for malignant potential. Br J Cancer 1994;70:506-512.
47. Créange A, Bélec L, Clair B, et al. Circulating transforming growth factor-beta 1 (TGF-β1) in Guillain-Barré syndrome: decreased levels in the early course and increase with motor function. J Neurol Neurosurg Psychiatry 1998;64:162-165.
48. Gunther M, Haubeck HD, van de Leur E, et al. Transforming growth factor beta 1 regulates tissue inhibitor of metalloproteinases-1 expression in differentiated human articular chondrocytes. Arthritis Rheum 1994;37:395-405.
49. Millis AJ, Hoyle M, McCue HM, Martini H. Differential expression of metalloproteinase and tissue inhibitor of metalloproteinase genes in aged human fibroblasts. Exp Cell Res 1992;201:373-379.
50. Gijbels K, Galardy RE, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 1994;94:2177-2182.
51. Créange A, Lerat H, Meyrignac C, et al. Treatment of Guillain-Barré syndrome with interferon-beta. Lancet 1998; 352:368-369.
52. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon beta-lb inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40:846-852.
53. Ossege LM, Sindern E, Patzold T, Malin JP. Immunomodulatory effects of interferon-beta-1b in vivo: induction of the expression of transforming growth factor-betal and its receptor type II. J Neuroimmunol 1998;91:73-81.